Brandon Frith

Brandon Frith inquired about preliminary conversations with payers regarding formulary access for Jakafi XR and any early signs that instill confidence in its eventual launch.

Answer

Bill Meury, President and CEO, confirmed discussions with major PBMs, highlighting the medical rationale for Jakafi XR due to its chronic indication and potential for adherence gains. He discussed setting a strategic price point to ensure formulary coverage, aiming for a 10-30% conversion rate, with meaningful conversion expected in 2027.

Brandon Frith asked about preliminary conversations with payers regarding formulary access for Jakafi XR and any early signs of confidence for its eventual launch.

Answer

Bill Meury, President and CEO, Incyte, confirmed discussions with major PBMs, emphasizing Jakafi's suitability for an XR formulation due to its chronic disease indication and potential for adherence gains. He noted the need to set a price that balances PBM, patient, and Incyte interests to achieve sufficient formulary coverage for a 10%-30% conversion rate, with meaningful conversion expected in 2027.

Brandon Frith asked if Roivant has provided any analogs for the DM launch and what to expect for its cadence out of the gates and longer term.

Answer

CEO Matthew Gline stated there are no direct analogs for DM due to high unmet need but few recent novel therapies. He guided cautiously on launch speed, emphasizing the large overall market opportunity and high unmet patient need for peak penetration.

Brandon Frith asked for analogs for the DM launch and expectations for its cadence, both initially and long-term.

Answer

CEO Matt Gline stated there are no great analogs for DM due to its high unmet need and lack of recent novel therapies. He indicated a cautious approach to launch speed guidance but expressed confidence in the large overall market opportunity and the focus on achieving a strong long-term trajectory.

Brandon Frith asked if HS data would include high score data at the top-line readout and how BRINSUPRI might fit into the HS landscape.

Answer

Martina Flammer, Chief Medical Officer, confirmed that secondary endpoints of HiSCR 50 and HiSCR 75 would be assessed at the 16-week top-line readout. She anticipated that the full impact on HiSCR would be clearer at 52 weeks, which will be a key focus for the Phase III program.

On behalf of Andy Chen at Wolfe Research, Brandon Frith asked what specific data Intellia aims to generate with the expanded MAGNITUDE study to be compelling to payers and physicians.

Answer

EVP & CMO David Lebwohl explained that as tafamidis becomes the standard of care, it is critical to demonstrate a statistically significant and clinically meaningful benefit on top of it. CEO John Leonard added that the goal is to generate "absolutely unambiguous" data across the entire treatment spectrum—monotherapy, combination therapy, and standard of care—to clearly differentiate the product in the market.